You are here

IID-22 Data Details

Expand All

IID-22 Increase the number of public health laboratories monitoring influenza virus resistance to antiviral agents

About the Data

Description of the data source, numerator, denominator, survey questions, and other relevant details about the national estimate.

Data Source: 
State Public Health Laboratories Performing Antiviral Resistance Testing; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (CDC/NCIRD)
Changed Since the Healthy People 2020 Launch: 
No
Measure: 
number
Baseline (Year): 
3 (2009)
Target: 
25
Target-Setting Method: 
Maintain consistency with national programs, regulations, policies, and laws.
Target-Setting Method Justification: 
As of July 2009, only three public health state laboratories (California, New York, and Wisconsin) monitor susceptibility to adamantanes (amantadine and rimantadine). More than 90 public health laboratories exist in the United States. Some States have multiple public health laboratories. Some large cities and counties have public health laboratories. In addition, the public health system is centralizing laboratories regionally across the United States. Reporting requirements vary State by State, and CDC can only request (not require) reporting. Increasing the number of public health laboratories that monitor antiviral resistance will require partnership, laboratory materials, and a regular reporting system. Increasing the number of public health laboratories to 25 by 2020 is achievable.
Numerator: 

Number of state public health laboratories that have submitted reports to CDC listing virus susceptibility to either class of antiviral drug (adamantanes or neuraminidase inhibitors)

Comparable Healthy People 2010 Objective: 
Not applicable
Data Collection Frequency: 
Annual
Methodology Notes: 

    Antivirals are the only prescribed medication available to treat a patient once they have contracted influenza. Monitoring for viruses resistant to antivirals is key to inform prescription and other non-pharmaceutical and pharmaceutical intervention guidance. In 2009, CDC was the only public health laboratory conducting a comprehensive monitoring of influenza A and B virus susceptibilities to four licensed anti-influenza drugs in the United States.